Zai Lab’s Zoci Combination Achieves 81.8% Response Rate in First-Line Lung Cancer Trial

• Zai Lab reported encouraging responses with zocilurtatug pelitecan combined with atezolizumab in a Phase 1b trial for first-line extensive-stage small cell lung cancer.
• The platinum-free combination showed durable responses and was generally well tolerated; adding carboplatin led to more frequent severe adverse events.
• Results will be presented at the European Society for Medical Oncology Congress on October 26, 2026.
• A global randomized Phase 3 trial evaluating zocilurtatug pelitecan with an immuno-oncology regimen is expected to begin by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230633BIZWIRE_USPR_____20261022_BW534590) on October 23, 2026, and is solely responsible for the information contained therein.